CRBN and Miyoshi myopathy: In MM, IMiD-based CRBN-targeted and VHL-targeted PROTACs (i.e., ARV-825 and ARV-763, respectively), which degrade the BET-domain-containing protein BRD-4 induced cell cycle arrest and apoptosis and overcame drug resistance in pre-clinical models of MM [100,101,102,103,104].